155
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Radioprotection of Hematopoietic Tissue by Fibroblast Growth Factors in Fractionated Radiation Experiments

, , , , &
Pages 337-340 | Received 25 Jul 1996, Accepted 12 Jan 1997, Published online: 08 Jul 2009
 

Abstract

Acidic and basic fibroblast growth factors (FGF1/2) myeloprotect mice in single dose total body irradiation (TBI) experiments with a dose modification factor (DMF) of ≈ 1.15. CFU-C assay suggests that one of the mechanisms is augmentation of the shoulder of the radiation dose response curve, and thus protection could be greater with fractionation. Four equal fractions of TBI were delivered to C3H/He mice at times 0 h, 8 h, 24 h, and 32 h, FGF1/2 dose was 3 μg per iv injection given 24 and 4 hrs before the first radiation dose. FGF2 treated mice had a significant survival advantage over saline-treated mice with a DMF of 1.22 ± 0.07 (p < 0.01). Adding a third dose of FGF2, had no additional benefit on LD50/30 (dose of radiation lethal to 50% of animals measured at day 30) (DMF = 1.23 ± 0.06, p < 0.01). FGF1 was not as effective with fractionation (DMF = 1.04 ± 0.03). Increased survival in FGF2 treated mice was due to the a more rapid recovery of bone marrow hematopoietic cells and peripheral WBC, RBC and platelets. FGF2 may prove a useful treatment response modifier in clinical fractionated irradiation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.